Supernus Pharms Drug Patent Portfolio
Supernus Pharms owns 5 orange book drugs protected by 57 US patents with Qelbree having the least patent protection, holding only 5 patents. And Osmolex Er with maximum patent protection, holding 20 patents. Given below is the list of Supernus Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11065213 | Amantadine compositions and preparations thereof | 23 Aug, 2038 | Active |
| US11077073 | Methods of using amantadine compositions | 23 Aug, 2038 | Active |
| US10213393 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10213394 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10500170 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10500171 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10500172 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10512617 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US11890261 | Composition and method for treating neurological disease | 15 Feb, 2038 | Active |
| US10154971 | Methods of administering amantadine | 04 Dec, 2034 | Active |
| US10646456 | Methods of administering amantadine | 17 Jun, 2034 | Active |
| US11903908 | Methods of administering amantadine | 17 Jun, 2034 | Active |
| US9358204 | Formulations of viloxazine | 07 Feb, 2033 | Active |
| US9603853 | Formulations of viloxazine | 07 Feb, 2033 | Active |
| US9662338 | Formulations of viloxazine | 07 Feb, 2033 | Active |
| US11197835 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US8741343 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US9867791 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US9867792 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US9867793 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US9877933 | Method of administering amantadine prior to a sleep period | 02 Dec, 2030 | Active |
| US8252331 | Osmotic device containing amantadine and an osmotic salt | 13 Mar, 2030 | Active |
| US11324753 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | 04 Sep, 2029 | Active |
| US11458143 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | 04 Sep, 2029 | Active |
| US8298576 | Sustained-release formulations of topiramate | 04 Apr, 2028 | Active |
| US8389578 | Composition and method for treating neurological disease | 22 Jan, 2028 | Active |
| US10314790 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US8298580 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US8663683 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US8877248 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US8889191 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US8992989 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US9549940 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US9555004 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US9622983 | Sustained-release formulations of topiramate | 16 Nov, 2027 | Active |
| US10220042 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US11166960 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US11896599 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US7910131 | Method of treating seizures using modified release formulations of oxcarbazepine | 13 Apr, 2027 | Active |
| US8617600 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US8821930 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US9119791 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US9351975 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US9370525 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US9855278 | Modified release preparations containing oxcarbazepine and derivatives thereof | 13 Apr, 2027 | Active |
| US8574626 | Osmotic device containing amantadine and an osmotic salt | 28 Nov, 2025 | Active |
| US8796337 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8889740 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8895614 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8895615 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8895616 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8895617 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8895618 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US8987333 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| US9072697 | Composition and method for treating neurological disease | 23 Nov, 2025 | Active |
| USRE39069 | Multi-layered osmotic device | 29 May, 2018 | Expired |
Latest Legal Activities on Supernus Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Supernus Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Apr, 2024 | US8298580 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US8252331 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903908 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Feb, 2024 | US11903908 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Feb, 2024 | US11903908 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903908 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903908 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11903908 |
|
Recordation of Patent Grant Mailed
Critical
| 13 Feb, 2024 | US11896599 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 13 Feb, 2024 | US11896599 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11896599 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896599 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896599 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896599 |
|
Email Notification
Critical
| 06 Feb, 2024 | US11890261 |
Supernus Pharms's Drug Patent Litigations
Supernus Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 16, 2021, against patent number US11324753. The petitioner , challenged the validity of this patent, with Supernus Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Supernus Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11324753 | February, 2021 |
Decision
(05 Oct, 2021)
| Supernus Pharmaceuticals, Inc. | |
Supernus Pharms Drug Patents' Oppositions Filed in EPO
Supernus Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 20, 2017, by Ahrens, Gabriele. This opposition was filed on patent number EP10835150A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10835150A | Apr, 2017 | Ahrens, Gabriele | Patent maintained as amended |
Supernus Pharms's Family Patents
Supernus Pharms drugs have patent protection in a total of 14 countries. It has a significant patent presence in the US with 63.2% of its patents being US patents. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Supernus Pharms Drug List
Given below is the complete list of Supernus Pharms's drugs and the patents protecting them.
1. Gocovri
Gocovri is protected by 19 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11065213 | Amantadine compositions and preparations thereof |
23 Aug, 2038
(13 years from now)
| Active |
| US11077073 | Methods of using amantadine compositions |
23 Aug, 2038
(13 years from now)
| Active |
| US10154971 | Methods of administering amantadine |
04 Dec, 2034
(9 years from now)
| Active |
| US10646456 | Methods of administering amantadine |
17 Jun, 2034
(9 years from now)
| Active |
| US11903908 | Methods of administering amantadine |
17 Jun, 2034
(9 years from now)
| Active |
| US11197835 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US8741343 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US9867791 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US9867792 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US9867793 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US9877933 | Method of administering amantadine prior to a sleep period |
02 Dec, 2030
(5 years from now)
| Active |
| US8389578 | Composition and method for treating neurological disease |
22 Jan, 2028
(3 years from now)
| Active |
| US8796337 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8889740 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895614 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895615 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895616 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895617 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895618 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gocovri's drug page
2. Osmolex Er
Osmolex Er is protected by 20 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10213393 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US10213394 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US10500170 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US10500171 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US10500172 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US10512617 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US11890261 | Composition and method for treating neurological disease |
15 Feb, 2038
(13 years from now)
| Active |
| US8252331 | Osmotic device containing amantadine and an osmotic salt |
13 Mar, 2030
(5 years from now)
| Active |
| US8389578 | Composition and method for treating neurological disease |
22 Jan, 2028
(3 years from now)
| Active |
| US8574626 | Osmotic device containing amantadine and an osmotic salt |
28 Nov, 2025
(11 months from now)
| Active |
| US8796337 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8889740 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895614 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895615 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895616 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895617 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8895618 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US8987333 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| US9072697 | Composition and method for treating neurological disease |
23 Nov, 2025
(11 months from now)
| Active |
| USRE39069 | Multi-layered osmotic device |
29 May, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Osmolex Er's drug page
3. Oxtellar Xr
Oxtellar Xr is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10220042 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US11166960 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US11896599 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US7910131 | Method of treating seizures using modified release formulations of oxcarbazepine |
13 Apr, 2027
(2 years from now)
| Active |
| US8617600 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US8821930 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US9119791 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US9351975 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US9370525 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
| US9855278 | Modified release preparations containing oxcarbazepine and derivatives thereof |
13 Apr, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxtellar Xr's drug page
4. Qelbree
Qelbree is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9358204 | Formulations of viloxazine |
07 Feb, 2033
(8 years from now)
| Active |
| US9603853 | Formulations of viloxazine |
07 Feb, 2033
(8 years from now)
| Active |
| US9662338 | Formulations of viloxazine |
07 Feb, 2033
(8 years from now)
| Active |
| US11324753 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
04 Sep, 2029
(4 years from now)
| Active |
| US11458143 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
04 Sep, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qelbree's drug page
5. Trokendi Xr
Trokendi Xr is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8298576 | Sustained-release formulations of topiramate |
04 Apr, 2028
(3 years from now)
| Active |
| US10314790 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US8298580 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US8663683 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US8877248 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US8889191 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US8992989 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US9549940 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US9555004 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
| US9622983 | Sustained-release formulations of topiramate |
16 Nov, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trokendi Xr's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List